|
[1]TREVISANI F,D'INTINO PE,MORSELLI-LABATE AM,et al.Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease:Influence of HBs Ag and anti-HCV status[J].J Hepatol,2001,34(4):570-575．
|
|
[2]YI X,YU S,BAO Y.Alpha-fetoprotein-L3 in hepatocellular carcinoma:A meta-analysis[J].Clin Chim Acta,2013,425(21):212-220．
|
|
[3]KOKUDO N,HASEGAWA K,AKAHANE M,et al.Evidence-based clinical practice guidelines for hepatocellular carcinoma:The Japan Society of Hepatology 2013 update(3rd JSH-HCC Guidelines)[J].Hepatol Res,2015,45(2):123-127．
|
|
[4]KOH WJ,GREER BE,ABU-RUSTUM NR,et al.Vulvar cancer,version 1.2017,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2017,15(1):92-120．
|
|
[5] Anti-cancer Association of China.Guideline for the diagnosis and therapy of hilar cholangiocarcinoma(2015)[J].Chin J Hepatobiliary Surg,2015,21(8):505-511.(in Chinese)中国抗癌协会．肝门部胆管癌规范化诊治专家共识(2015)[J]．中华肝胆外科杂志，2015,21(8):505-511．
|
|
[6]MARRERO JA,ROMANO PR,NIKOLAEVA O,et al.GP73,a resident Golgi glycoprotein,is a novel serum marker for hepatocellular carcinoma[J].J Hepatol,2005,43(6):1007-1012．
|
|
[7]GERAMIZADEH B,SEIRFAR N.Diagnostic value of arginase-1and glypican-3 in differential diagnosis of hepatocellular carcinoma,cholangiocarcinoma and metastatic carcinoma of liver[J].Hepat Mon,2015,15(7):e30336．
|
|
[8]COHEN JD,LI L,WANG Y,et al.Detection and localization of surgically resectable cancers with a multi-analyte blood test[J].Science,2018,359(6378):926-930．
|
|
[9]QU C,WANG Y,WANG P,et al.Detection of early-stage hepatocellular carcinoma in asymptomatic HBs Ag-seropositive individuals by liquid biopsy[J].Proc Natl Acad Sci U S A,2019,116(13):6308-6312．
|
|
[10]XU RH,WEI W,KRAWCZYK M,et al.Circulating tumour DNAmethylation markers for diagnosis and prognosis of hepatocellular carcinoma[J].Nat Mater,2017,16(11):1155-1161．
|
|
[11]CHENG J,WEI D,JI Y,et al.Integrative analysis of DNA methylation and gene expression reveals hepatocellular carcinoma-specific diagnostic biomarkers[J].Genome Med,2018,10(1):42．
|
|
[12]QU Y,SHI L,WANG D,et al.Low frequency of TERT promoter mutations in a large cohort of gallbladder and gastric cancers[J].Int JCancer,2014,134(12):2993-2994．
|
|
[13]ZHOU J,YU L,GAO X,et al.Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J].J Clin Oncol,2011,29(36):4781-4788．
|
|
[14]JI J,SHI J,BUDHU A,et al.MicroRNA expression,survival,and response to interferon in liver cancer[J].N Engl J Med,2009,361(15):1437-1447．
|
|
[15]ZUCMAN-ROSSI J,VILLANUEVA A,NAULT JC,et al.Genetic landscape and biomarkers of hepatocellular carcinoma[J].Gastroenterology,2015,149(5):1226-1239.e4．
|
|
[16]HORWITZ E,STEIN I,BEN-NERIAH Y,et al.Animal model studies indicate a candidate biomarker for sorafenib treatment of hepatocellular carcinoma[J].Mol Cell Oncol,2015,2(1):e968028．
|
|
[17]LIM HY,HEO J,CHOI HJ,et al.A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib(BAY 86-9766)plus sorafenib for Asian patients with unresectable hepatocellular carcinoma[J].Clin Cancer Res,2014,20(23):5976-5985．
|
|
[18]XIANG Q,CHEN W,REN M,et al.Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET[J].Clin Cancer Res,2014,20(11):2959-2970．
|
|
[19]HARDING JJ,NANDAKUMAR S,ARMENIA J,et al.Prospective genotyping of hepatocellular carcinoma:Clinical implications of nextgeneration sequencing for matching patients to targeted and immune therapies[J].Clin Cancer Res,2019,25(7):2116-2126．
|
|
[20]ZHOU SL,ZHOU ZJ,HU ZQ,et al.Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence[J].J Hepatol,2019,71(6):1152-1163．
|
|
[21]LEIJEN S,van GEEL RM,PAVLICK AC,et al.Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine,cisplatin,or carboplatin in patients with advanced solid tumors[J].J Clin Oncol,2016,34(36):4371-4380．
|
|
[22]Cancer Genome Atlas Research Network.Comprehensive and integrative genomic characterization of hepatocellular carcinoma[J].Cell,2017,169(7):1327-1341.e23．
|
|
[23]RAZUMILAVA N,GORES GJ.Cholangiocarcinoma[J].Lancet,2014,383(9935):2168-2179．
|
|
[24]JIAO Y,PAWLIK TM,ANDERS RA,et al.Exome sequencing identifies frequent inactivating mutations in BAP1,ARID1A and PBRM1in intrahepatic cholangiocarcinomas[J].Nat Genet,2013,45(12):1470-1473．
|
|
[25]WARDELL CP,FUJITA M,YAMADA T,et al.Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations[J].J Hepatol,2018,68(5):959-969．
|
|
[26]LAU DK,TAY RY,YEUNG YH,et al.Phase II study of everolimus(RAD001)monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration:The RADi Chol Study[J].Br J Cancer,2018,118(7):966-971．
|
|
[27]GEORGE S,MIAO D,DEMETRI GD,et al.Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma[J].Immunity,2017,46(2):197-204．
|
|
[28]LIN J,SHI J,GUO H,et al.Alterations in DNA damage repair genes in primary liver cancer[J].Clin Cancer Res,2019,25(15):4701-4711．
|
|
[29]JAVLE M,BEKAII-SAAB T,JAIN A,et al.Biliary cancer:Utility of next-generation sequencing for clinical management[J].Cancer,2016,122(24):3838-3847．
|
|
[30]SAHA SK,ZHU AX,FUCHS CS,et al.Forty-year trends in cholangiocarcinoma incidence in the U.S.:Intrahepatic disease on the rise[J].Oncologist,2016,21(5):594-599．
|
|
[31]JAVLE M,LOWERY M,SHROFF RT,et al.Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma[J].J Clin Oncol,2018,36(3):276-282．
|
|
[32]AACR Project GENIE Consortium.AACR project GENIE:Powering precision medicine through an international consortium[J].Cancer Discov,2017,7(8):818-831．
|
|
[33]JAVLE M,CHURI C,KANG HC,et al.HER2/neu-directed therapy for biliary tract cancer[J].J Hematol Oncol,2015,8:58．
|
|
[34]SORSCHER S.Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab[J].Cancer Manag Res,2013,9:1-3．
|
|
[35]LAW LY.Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma[J].J Clin Oncol,2012,30(27):e271-e273．
|
|
[36]GOEPPERT B,FRAUENSCHUH L,RENNER M,et al.BRAFV600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma[J].Mod Pathol,2014,27(7):1028-1034．
|
|
[37]FLAHERTY KT,INFANTE JR,DAUD A,et al.Combined BRAFand MEK inhibition in melanoma with BRAF V600 mutations[J].NEngl J Med,2012,367(18):1694-1703．
|
|
[38]CHEN G,HUANG AC,ZHANG W,et al.Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response[J].Nature,2018,560(7718):382-386．
|
|
[39]LE DT,URAM JN,WANG H,et al.PD-1 blockade in tumors with mismatch-repair deficiency[J].N Engl J Med,2015,372(26):2509-2520．
|
|
[40]ANG C,KLEMPNER SJ,ALI SM,et al.Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma[J].Oncotarget,2019,10(40):4018-4025．
|
|
[41]MOU H,YU L,LIAO Q,et al.Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression:A case report[J].BMC Cancer,2018,18(1):1105．
|
|
[42] HAVEL JJ,CHOWELL D,CHAN TA.The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy[J].Nat Rev Cancer,2019,19(3):133-150．
|
|
[43]PINYOL R,SIA D,LLOVET JM.Immune exclusion-Wnt/CTNNB1class predicts resistance to immunotherapies in HCC[J].Clin Cancer Res,2019,25(7):2021-2023．
|
|
[44]TAN WF,LIU MQ,HE PS.Discuss the standardized management of immunohistochemical quality control[J].China Mod Doct,2013,51(31):134-136,139.(in Chinese)谭卫峰，刘庆猛，何平生．免疫组化质量控制的标准化管理[J]．中国现代医生，2013,51(31):134-136,139．
|
|
[45] General Administration of Quality Supervision,Inspection and Quarantine of the People's Republic of China,China National Standardization Administration Committee.GB19489-2008 General requirements for laboratory biosafety[S].Beijing:Standards Press of China,2008.(in Chinese)中华人民共和国国家质量监督检验检疫总局，中国国家标准化管理委员会．GB19489-2008《实验室生物安全通用要求》[S]．北京:中国标准出版社，2008．
|
|
[46]Expert Consensus on Second Generation Gene Sequencing in Clinical Molecular Pathology Laboratory.Expert consensus on the second generation gene sequencing test in clinical molecular pathology laboratory[J].Chin J Pathol,2017,46(3):145-148.(in Chinese)《临床分子病理实验室二代基因测序检测专家共识》编写组．临床分子病理实验室二代基因测序检测专家共识[J]．中华病理学杂志，2017,46(3):145-148．
|
|
[47]VILLANUEVA A.Hepatocellular carcinoma[J].N Engl J Med,2019,380(15):1450-1462．
|
|
[48]O'DONNELL JS,TENG M,SMYTH MJ.Cancer immunoediting and resistance to T cell-based immunotherapy[J].Nat Rev Clin Oncol,2019,16(3):151-167．
|
|
[49]CHAMPIAT S,DERCLE L,AMMARI S,et al.Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1[J].Clin Cancer Res,2017,23(8):1920-1928．
|
|
[50]FERRARA R,MEZQUITA L,TEXIER M,et al.Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy[J].JAMA Oncol,2018,4(11):1543-1552．
|
|
[51]KATO S,GOODMAN A,WALAVALKAR V,et al.Hyperprogressors after immunotherapy:Analysis of genomic alterations associated with accelerated growth rate[J].Clin Cancer Res,2017,23(15):4242-4250.
|
DownLoad: